Rituximab, Lenalidomide, and Bortezomib in Mantle Cell Lymphoma

NCT00633594 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

39

Enrollment

OTHER

Sponsor class

Conditions

Mantle Cell Lymphoma

Interventions

DRUG: Rituximab
DRUG: Bortezomib
DRUG: Lenalidomide

Sponsor

SCRI Development Innovations, LLC

Collaborators

[object Object]
[object Object]